Repatha may help reduce the risk of heart attack, stroke, and heart surgery for adults with heart disease. It might also lower low-density lipoprotein (LDL) cholesterol in adults and children with ...

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current ...

Patients treated with Repatha experienced change from baseline similar to placebo in all three cognitive domains tested: spatial working memory between-errors score (baseline 21.0, Repatha -0.5 versus ...

Amgen Inc.AMGN presented encouraging one-year data from the phase II (OSLER-1) and phase III (OSLER-2) open-label extension studies and phase III YUKAWA-2 study on its PCSK9 inhibitor, Repatha ...

In this analysis of the landmark FOURIER outcomes study, 5,711 patients who experienced an MI within one to 12 months of randomization were compared to 16,609 patients with a more distant event (>12 ...

THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...

Amgen (NASDAQ: AMGN) today announced that the Company will discuss the data supporting the Repatha TM (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...

Amgen Inc.AMGN has filed an application with the FDA seeking approval for a new delivery alternative of its PCSK9 inhibitor, Repatha (evolocumab). Amgen is looking to get the 420 mg monthly dose of ...